Mechanisms of Alcoholic Steatosis/Steatohepatitis

  • Zhanxiang Zhou
  • Ross E. Jones
  • Craig J. McClain


Despite extensive research, alcohol remains one of the most common causes of both acute and chronic liver disease in the USA. In Western countries, up to 50% of cases of end-stage liver disease have alcohol as a major etiologic factor. Excessive alcohol consumption is the third leading preventable cause of death in the USA. Alcohol-related deaths, excluding accidents/homicides, accounted for 22,073 deaths in the USA in 2006 with 13,000 of those specifically attributed to alcoholic liver disease (ALD). Given these grim statistics, the mortality of this liver disease is more than that of many major forms of cancer, such as breast, colon and prostate. Importantly, there is no Food and Drug Administration (FDA)-approved therapy for any stage of ALD.


Fatty Acid Oxidation Alcoholic Liver Disease Alcohol Exposure Microsomal Triglyceride Transfer Protein Hepatic Lipid Accumulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hall P. Pathological spectrum of alcoholic liver disease. In: Hall P, editor. Alcoholic liver disease. 2nd ed. London: Edward Arnold; 1995. p. 41–88.Google Scholar
  2. 2.
    Purohit V, Russo D, Coates PM. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Alcohol. 2004;34:3–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Lakshman MR. Some novel insights into the pathogenesis of alcoholic steatosis. Alcohol. 2004;34:45–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Baraona E, Lieber CS. Effects of ethanol on lipid metabolism. J Lipid Res. 1979;20(3):289–315.PubMedGoogle Scholar
  5. 5.
    You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem. 2002;277(32):29342–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Esfandiari F, You M, Villanueva JA, et al. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res. 2007;31(7):1231–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Yin HQ, Je YT, Kim M, et al. Analysis of hepatic gene expression during fatty liver change due to chronic ethanol administration in mice. Toxicol Appl Pharmacol. 2009;235(3):312–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002;65:167–94.PubMedCrossRefGoogle Scholar
  9. 9.
    You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G1–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Purohit V, Gao B, Song BJ. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res. 2009;33(2):191–205.PubMedCrossRefGoogle Scholar
  11. 11.
    Venkatesan S, Leung NW, Peters TJ. Fatty acid synthesis in vitro by liver tissue from control subjects and patients with alcoholic liver disease. Clin Sci (Lond). 1986;71(6):723–8.Google Scholar
  12. 12.
    Tijburg LB, Maquedano A, Bijleveld C, et al. Effects of ethanol feeding on hepatic lipid synthesis. Arch Biochem Biophys. 1988;267(2):568–79.PubMedCrossRefGoogle Scholar
  13. 13.
    Simpson KJ, Venkatesan S, Peters TJ. Fatty acid synthesis by rat liver after chronic ethanol feeding with a low-fat diet. Clin Sci (Lond). 1994;87(4):441–6.Google Scholar
  14. 14.
    You M, Matsumoto M, Pacold CM, et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127(6):1798–808.PubMedCrossRefGoogle Scholar
  15. 15.
    Reddy JK, Hashimoto T. Peroxisomal-oxidation and peroxisome proliferator-activated receptor: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193–230.PubMedCrossRefGoogle Scholar
  16. 16.
    Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab. 2008;295(1):E10–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Lieber CS, Lefevre A, Spritz N, et al. Difference in hepatic metabolism of long and medium-chain fatty acids: the role of fatty acid chain length in the production of alcoholic fatty liver. J Clin Invest. 1967;46:1451–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Blomstrand R, Kager L, Lantto O. Studies on the ethanol-induced decrease of fatty acid oxidation in rat and human liver slices. Life Sci. 1973;13:1131–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Ontko JA. Effects of ethanol on the metabolism of free fatty acids in isolated liver cel1s. J Lipid Res. 1973;14:78–85.PubMedGoogle Scholar
  20. 20.
    Cederbaum AI, Lieber CS, Beattie DS, Rubin E. Effect of chronic ethanol ingestion on fatty acid oxidation by hepatic mitochondria. J Biol Chem. 1975;250(13):5122–9.PubMedGoogle Scholar
  21. 21.
    Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta. 1997;257:59–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Orellana M, Rodrigo R, Valdés E. Peroxisomal and microsomal fatty acid oxidation in liver of rats after chronic ethanol consumption. Gen Pharmacol. 1998;31(5):817–20.PubMedGoogle Scholar
  23. 23.
    Ma X, Baraona E, Lieber CS. Alcohol consumption enhances fatty acid omega-oxidation, with a greater increase in male than in female rats. Hepatology. 1993;18(5):1247–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem. 2003;278(30):27997–8004.PubMedCrossRefGoogle Scholar
  25. 25.
    Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol. 2004;34(1):35–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Venkatesan S, Ward RJ, Peters TJ. Effect of chronic ethanol feeding on the hepatic secretion of very-low-density lipoproteins. Biochim Biophys Acta. 1988;960(1):61–6.PubMedGoogle Scholar
  27. 27.
    García-Villafranca J, Guillén A, Castro J. Desensitization of cyclic GMP-mediated regulation of fatty acid metabolism in hepatocytes from ethanol-fed rats. Int J Biochem Cell Biol. 2005;37(3):655–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Kharbanda KK, Todero SL, Ward BW, et al. Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem. 2009;327(1–2):75–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kang X, Zhong W, Liu J, et al. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology. 2009;50(4):1241–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin MC, Li JJ, Wang EJ, et al. Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J. 1997;11(13):1145–52.PubMedGoogle Scholar
  31. 31.
    Sugimoto T, Yamashita S, Ishigami M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol. 2002;36(2):157–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Tahara M, Matsumoto K, Nukiwa T, Nakamura T. Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J Clin Invest. 1999;103(3):313–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Lau PP, Cahill DJ, Zhu HJ, Chan L. Ethanol modulates apolipoprotein B mRNA editing in the rat. J Lipid Res. 1995;36(10):2069–78.PubMedGoogle Scholar
  34. 34.
    Tomita K, Azuma T, Kitamura N, et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology. 2004;26(3):873–85.CrossRefGoogle Scholar
  35. 35.
    Zhou SL, Gordon RE, Bradbury M, et al. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells. Hepatology. 1998;27(4):1064–74.PubMedCrossRefGoogle Scholar
  36. 36.
    Berk PD, Zhou S, Bradbury MW. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. Trans Am Clin Climatol Assoc. 2005;116:335–44.PubMedGoogle Scholar
  37. 37.
    Abrams MA, Cooper C. Quantitative analysis of metabolism of hepatic triglyceride in ethanol-treated rats. Biochem J. 1976;156(1):33–46.PubMedGoogle Scholar
  38. 38.
    Baraona E, Lieber CS. Effects of chronic ethanol feeding on serum lipoprotein metabolism in the rat. J Clin Invest. 1970;49(4):769–78.PubMedCrossRefGoogle Scholar
  39. 39.
    Addolorato G, Capristo E, Greco AV, et al. Energy expenditure, substrate oxidation, and body composition in subjects with chronic alcoholism: new findings from metabolic assessment. Alcohol Clin Exp Res. 1997;21(6):962–7.PubMedGoogle Scholar
  40. 40.
    Leggio L, Malandrino N, Ferrulli A, et al. Is cortisol involved in the alcohol-related fat mass impairment? A longitudinal clinical study. Alcohol. 2009;44(2):211–5.Google Scholar
  41. 41.
    Kang L, Chen X, Sebastian BM, et al. Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation. J Biol Chem. 2007;282(39):28465–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Kessler JI, Yalovsky-Mishkin S. Effect of ingestion of saline, glucose, and ethanol on mobilization and hepatic incorporation of epididymal pad palmitate-1-14C in rats. J Lipid Res. 1966;7(6):772–7.PubMedGoogle Scholar
  43. 43.
    Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol. 2006;21 Suppl 3:S56–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Costet P, Legendre C, More J, et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998;273:29577–85.PubMedCrossRefGoogle Scholar
  45. 45.
    Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–98.PubMedCrossRefGoogle Scholar
  46. 46.
    Tsutsumi A, Takase S. Effect of fenofibrate on fatty liver in rats treated with alcohol. Alcohol Clin Exp Res. 2001;25:75S–9.CrossRefGoogle Scholar
  47. 47.
    Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther. 2004;310(1):417–24.PubMedCrossRefGoogle Scholar
  48. 48.
    Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37:1249–53.PubMedCrossRefGoogle Scholar
  49. 49.
    Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303:1378–81.PubMedCrossRefGoogle Scholar
  50. 50.
    Hayhurst GP, Lee YH, Lambert G, et al. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001;21:1393–403.PubMedCrossRefGoogle Scholar
  51. 51.
    Lakshman MR, Chirtel SJ, Chambers LC. Hepatic synthesis of apoproteins of very-low-density and high density lipoproteins in perfused rat liver: Influence of chronic heavy and moderate doses of ethanol. Alcohol Clin Exp Res. 1989;13:554–9.PubMedCrossRefGoogle Scholar
  52. 52.
    You M, Rogers CQ. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med. 2009;234:850–9.CrossRefGoogle Scholar
  53. 53.
    Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-beta inces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med. 2007;232:614–21.Google Scholar
  54. 54.
    Misra P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets. 2008;12:91–100.PubMedGoogle Scholar
  55. 55.
    García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie. 2008;90:460–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Tomita K, Tamiya G, Ando S, et al. AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcohol Clin Exp Res. 2005;29:240S–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Ajmo JM, Liang X, Rogers CQ, et al. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G833–42.PubMedCrossRefGoogle Scholar
  58. 58.
    Ki SH, Choi JH, Kim CW, Kim SG. Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity. Chem Biol Interact. 2007;169:80–90.PubMedCrossRefGoogle Scholar
  59. 59.
    Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Chen X, Sebastian BM, Nagy LE. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am J Physiol Endocrinol Metab. 2007;292:E621–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Song Z, Zhou Z, Deaciuc I, et al. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology. 2008;47:867–79.PubMedCrossRefGoogle Scholar
  62. 62.
    Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91–100.PubMedGoogle Scholar
  63. 63.
    Chen X, Sebastian BM, Tang H, et al. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology. 2009;49:1554–62.PubMedCrossRefGoogle Scholar
  64. 64.
    You M, Considine RV, Leone TC, et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005;42:568–77.PubMedCrossRefGoogle Scholar
  65. 65.
    Shen Z, Liang X, Rogers CQ, et al. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G364–74.PubMedCrossRefGoogle Scholar
  66. 66.
    Morimoto M, Zern MA, Hagbjork AL, et al. Fish oil, alcohol, and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Biol Med. 1999;207:197–205.Google Scholar
  67. 67.
    Nanji AA, Zhao S, Sadrzadeh SM, et al. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil–ethanol-fed rats. Alcohol Clin Exp Res. 1994;18:1280–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Tsukamoto H, Horne W, Kamimura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995;96:620–30.PubMedCrossRefGoogle Scholar
  69. 69.
    Zhou Z, Wang L, Song Z, et al. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am J Pathol. 2005;166(6):1681–90.PubMedCrossRefGoogle Scholar
  70. 70.
    Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. Semin Liver Dis. 2009;29(2):141–54.PubMedCrossRefGoogle Scholar
  71. 71.
    Bardag-Gorce QX, Yuan J, Li BA, et al. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. Biochem Biophys Res Commun. 2000;279:23–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Butura A, Nilsson K, Morgan K, et al. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol. 2009;50(3):572–83.PubMedCrossRefGoogle Scholar
  73. 73.
    Lu Y, Zhuge J, Wang X, et al. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology. 2008;47(5):148314–94.CrossRefGoogle Scholar
  74. 74.
    Tomita K, Azuma T, Kitamura N, et al. Leptin deficiency enhances sensitivity of rats to alcoholic steatohepatitis through suppression of metallothionein. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1078–85.PubMedCrossRefGoogle Scholar
  75. 75.
    tom Dieck H, Döring F, Fuchs D, et al. Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. J Nutr. 2003;133:1004–10.PubMedGoogle Scholar
  76. 76.
    Dieck H, Döring F, Roth HP, Daniel H. Transcriptome and proteome analysis identifies the pathways that increase hepatic lipid accumulation in zinc-deficient rats. J Nutr. 2005;135:199–205.Google Scholar
  77. 77.
    McClain CJ, Antonow DR, Cohen DA, Shedlofsky S. Zinc metabolism in alcoholic liver disease. Alcohol Clin Exp Res. 1986;10:582–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Kiilerich S, Dietrichson O, Loud FB, et al. Zinc depletion in alcoholic liver diseases. Scand J Gastroenterol. 1980;15:363–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Bode JC, Hanisch P, Henning H, Koenig W, et al. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Rodríguez-Moreno F, González-Reimers E, Santolaria-Fernández F, et al. Zinc, copper, manganese, and iron in chronic alcoholic liver disease. Alcohol. 1997;14:39–44.PubMedCrossRefGoogle Scholar
  81. 81.
    Webster KA, Prentice H, Bishopric NH. Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal. 2001;3:535–48.PubMedCrossRefGoogle Scholar
  82. 82.
    Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology. 2010;52(5):1829–35.PubMedCrossRefGoogle Scholar
  83. 83.
    McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287(3):G497–502.PubMedCrossRefGoogle Scholar
  84. 84.
    Leach BE, Forbes JC. Sulfonamide drugs as protective agents against carbon tetrachloride poisoning. Proc Soc Exp Biol Med. 1941;48:361–3.Google Scholar
  85. 85.
    Rutenburg AM, Sonnenblick E, Koven I, et al. The role of intestinal bacteria in the development of dietary cirrhosis in rats. J Exp Med. 1957;106(1):1–14.PubMedCrossRefGoogle Scholar
  86. 86.
    Broitman SA, Gottlieb LS, Zamcheck N. Influence of neomycin and ingested endotoxin in the pathogenesis of choline deficiency cirrhosis in the adult rat. J Exp Med. 1964;119:633–42.PubMedCrossRefGoogle Scholar
  87. 87.
    Nolan JP. The contribution of gut-derived endotoxins to liver injury. Yale J Biol Med. 1979;52(1):127–33.PubMedGoogle Scholar
  88. 88.
    Gabuzda GJ. Hepatic coma: clinical considerations, pathogenesis, and management. Adv Intern Med. 1962;11:11–73.PubMedGoogle Scholar
  89. 89.
    Purohit V, Bode JC, Bode C, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol. 2008;42(5):349–61.PubMedCrossRefGoogle Scholar
  90. 90.
    Zieve L. Pathogenesis of hepatic coma. Arch Intern Med. 1966;118(3):211–23.PubMedCrossRefGoogle Scholar
  91. 91.
    McClain CJ, Zieve L. Portal systemic encephalopathy: recognition and variations. In: Davidson CS, editor. Problems in liver diseases. New York: Stratton Intercontinental Medical Book Corp; 1979. p. 162–72.Google Scholar
  92. 92.
    Adachi Y, Moore LE, Bradford BU, et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology. 1995;108(1):218–24.PubMedCrossRefGoogle Scholar
  93. 93.
    Keshavarzian A, Choudhary S, Holmes EW, et al. Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. J Pharmacol Exp Ther. 2001;299(2):442–8.PubMedGoogle Scholar
  94. 94.
    Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med. 1994;205(3):243–7.PubMedGoogle Scholar
  95. 95.
    McClain CJ, Song Z, Barve SS, et al. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287(3):G497–502.PubMedCrossRefGoogle Scholar
  96. 96.
    Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997;26(6):1530–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999;117(4):942–52.PubMedCrossRefGoogle Scholar
  98. 98.
    Honchel R, Ray MB, Marsano L, et al. Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res. 1992;16(4):665–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol. 2010;16(11):1321–9.PubMedCrossRefGoogle Scholar
  100. 100.
    McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9(3):349–51.PubMedCrossRefGoogle Scholar
  101. 101.
    Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991;13(2):267–76.PubMedCrossRefGoogle Scholar
  102. 102.
    Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953–60.PubMedCrossRefGoogle Scholar
  104. 104.
    Markiewski MM, DeAngelis RA, Lambris JD. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol. 2006;43(1–2):45–56.PubMedCrossRefGoogle Scholar
  105. 105.
    Fausto N. Involvement of the innate immune system in liver regeneration and injury. J Hepatol. 2006;45(3):347–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Haynes BF. Gut microbes out of control in HIV infection. Nat Med. 2006;12(12):1351–2.PubMedCrossRefGoogle Scholar
  107. 107.
    Carithers RI, McClain CJ. Chapter 81: Alcoholic liver disease. In: Feldman M, Friedman LS, Brant LJ, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease, vol. 2. Philadelphia: Elsevier; 2006. p. 1771–92.Google Scholar
  108. 108.
    Bergheim I, McClain CJ, Arteel GE. Chapter 28: Treatment of alcoholic liver disease. In: Singer M, Brenner DA, editors. Alcohol and the gastrointestinal tract. Basel, Switzerland: Karger AG; 2006. p. 196–213.Google Scholar
  109. 109.
    Barve A, Khan R, Marsano L, et al. Treatment of alcoholic liver disease. Ann Hepatol. 2008;7(1):5–15.PubMedGoogle Scholar
  110. 110.
    Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637–48.PubMedCrossRefGoogle Scholar
  111. 111.
    De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15(1):1613–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Mathurin P, Mendenhall CL, Carithers Jr RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2003;36:480–7.CrossRefGoogle Scholar
  113. 113.
    Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003;38:1363–9.PubMedGoogle Scholar
  114. 114.
    Tang Y, Forsyth CB, Banan A, et al. Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J Pharmacol Exp Ther. 2009;329(3):952–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Zhong W, McClain CJ, Cave M, Kang YJ, Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G625–33.PubMedCrossRefGoogle Scholar
  116. 116.
    Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42(8):675–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Zhanxiang Zhou
    • 1
  • Ross E. Jones
    • 2
  • Craig J. McClain
    • 2
  1. 1.Department of NutritionUniversity of North Carolina GreensboroKannapolisUSA
  2. 2.Department of MedicineUniversity of LouisvilleLouisvilleUSA

Personalised recommendations